AUTHOR GUIDELINES
Editorial Scope and Policy

Translational Research publishes original investigations in the broad fields of laboratory and clinical medicine. It aims to expedite the translation of scientific discovery into new or improved standards of care by promoting a wide-ranging exchange between basic, preclinical, clinical, epidemiologic, and health outcomes research. Reports of purely laboratory or animal investigations should have the potential for application to human disease, and reports of preliminary human investigations should have the potential for advancing our understanding of the biology of human disease. Reports of public health research should have the potential for application to the clinic, disease prevention, or healthcare policy. Case reports/series are encouraged, especially if they provide important mechanistic insight or illuminate a novel therapeutic principle. Original empirical research can be submitted as a Full-Length Article. Full-Length Articles describe original research in all fields of medicine; there is no maximum word limit.

Review manuscripts are welcomed for both state-of-the-art comprehensive reviews, directed at research scientists in specific fields, and more general informative reviews, directed at the broader community of clinical investigators. Originality is critical in order to contribute to the medical literature, and the perspective should be fresh and the synthesis unique. Authors of reviews should realize that the Journal is multidisciplinary and that reviews for such a journal require appropriate interpretive material. Clarity of presentation is a major criterion for acceptance.

Letters to the Editor commenting on published articles may be submitted. These comments should be directed at confirming the results (from a different approach), extending the original report, or refuting results or the authors’ interpretation. Reports describing preliminary findings that offer hypothesis-generating insight into recognized problems may also be submitted as a Letters to the Editor. Maximum length is 1000 words; maximum number of references is 15. The Editor reserves the right to decide on publication of letters, shorten them, remove objectionable comments, and make other changes in accord with the style of Translational Research.

Featured New Investigator Submissions and Annual Award
New investigators are encouraged to submit their original research or review manuscripts to Translational Research. Such manuscripts, if deemed acceptable after peer review, are published as part of the Featured New Investigator series. Each Featured New Investigator article is published first in the line-up of each month’s issue of the Journal, along with a short biographical note about the author. In addition, the best article published in the preceding year is eligible for a new award of $1500 plus domestic travel expenses to present the work at the annual meeting of the Central Society for Clinical and Translational Research. New investigators must be the first or senior author on a paper and must be within seven years of completing post-doctoral or fellowship training at the time of submission.

Human Subject Research
Papers reporting studies in human subjects must be accompanied by statements that the research was carried out according to the principles of the Declaration of Helsinki, that informed consent was obtained, and that the author’s institutional review board has approved the study. This statement must be included in the Methods section. The Journal encourages authors to discuss the ethical concerns in research that involves significant risk to participants.

All clinical trials that prospectively assign human subjects to intervention and comparison groups for the purposes of evaluating the cause-and-effect relationship between a medical intervention and a health outcome must be registered with a public registry before submission of a paper based on the trial. Studies that are designed for other purposes (retrospective records review, pharmacokinetics studies or assessment of major toxicity) are exempt from the requirement. Trial registry name, registration identification number, and the URL for the registry should be included in the Acknowledgements. Examples of registries are the US National Library of Medicine registry (http://www.clinicaltrials.gov) and the International Standard Randomised Controlled Trial Number (ISRCTN) registry (http://www.controlled-trials.com).

Authorship Agreement
The publisher and editors of Translational Research subscribe to the definitions of authorship as set forth in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals; accordingly, we expect each listed author to accept full responsibility for the paper. At the time of submission, the Journal requires an explicit statement by the senior corresponding author warranting that the manuscript, as submitted, has been reviewed by and approved by all named authors; that the corresponding author is empowered by all of the authors to act on their behalf with respect to the submission of the manuscript; that the article is original; that the article does not infringe upon any copyright or other proprietary right of any third party; that neither the text nor the data reported have been published previously (abstracts excepted); and that the article or a substantially similar article is not under consideration by another journal at this time. Include this author agreement in the cover letter to be submitted online. Furthermore, manuscripts submitted to Translational Research are reviewed (and ultimately published) with the understanding that all potential copyright conflicts have been addressed by the author(s) and that all overlap with other publications by the authors or by others have been disclosed. Moreover, in the event that fraud or other irregularity is alleged within 5 years of the appearance of a paper in Translational Research, it is our expectation that the authors will at our request produce both the actual data on which the paper was based and documentation of adequate resources to have carried out the work in question. It is understood that statements and opinions expressed in articles and communications are those of the author(s) and not necessarily those of the editor(s) or publisher, and the editor(s) and publisher disclaim any responsibility or liability for such material. If the manuscript receives favorable consideration, a form transferring copyright and confirming authorship will be sent to the corresponding author. If US Government jurisdiction precludes copyright transfer, provide a specific statement of exemption.

Review and selection
All articles are evaluated by the Editor for suitability for consideration for publication in Translational Research. Potentially acceptable submissions will also be reviewed in detail by two additional referees with expertise in the specific area. All revised manuscripts are carefully reexamined with no guarantee of acceptance, and authors will only have two opportunities to make revisions to the same manuscript. Final acceptance is based on originality, significance, documentation of conclusions, and form of presentation.
Early Online Publication

Accepted articles will be published online ahead of the printed issue and can be viewed at http://translationalres.com/inpress. Early online publication significantly reduces the time from acceptance to publication to approximately 4 weeks.

Manuscript preparation and organization

Manuscripts should be submitted online at http://ees.elsevier.com/transres. The website guides authors stepwise through the submission process. Submission items include a cover letter (save as a separate file for upload), the manuscript (including title page, abstract, main text, references, and figure legends), tables, and figures. Revised manuscripts should also be accompanied by a separate file (separate from the cover letter) with responses to reviewers’ comments. Do not import figures or tables into the text of the article. Original source files (not PDF files) are required for online submission. Files should be labeled with appropriate and descriptive file names (e.g., SmithText.doc, Fig1.tif, Table3.doc). The manuscript must be written in English and typed double-spaced.

Please send queries concerning the submission or review process to the Senior Managing Editor, Michael Franklin, MS, at frank061@umn.edu.

The main sections of all manuscripts should be indicated with capitalized head set flush with the left margin. The organization of review articles should be appropriate to the content of the review. The following organization is expected for manuscripts describing original investigations.

Title page. Include affiliations of the author(s). Also indicate the address of the author to whom correspondence and reprint requests should be directed; include business and fax numbers.

Abstract. An abstract of 250 words or less should orient the reader to the problem, describe the major observations, and state the principal conclusions, all in one paragraph without subheadings. It should be easily understood without reference to the text.

Running head and abbreviations. Include an abbreviated title (45 characters or less) and a list of definitions of any abbreviations used in the manuscript. Because this is a multidisciplinary journal, abbreviations should be kept to a minimum. It is preferable to use only universally understood abbreviations. Only standard chemical or non-proprietary pharmaceutical nomenclature should be used. All abbreviations must be defined separately in the title, abstract, and text of the manuscript.

Introduction. This should be organized and expressed in a way that will introduce and orient the general scientific reader to the topic.

Methods. The Methods section should include a description of the statistical methods used.

Results. These may be presented in tables or figures that should not duplicate the text. All tables and figures must be numbered in the order of their mention in the text.

Tables should be typed double-spaced as separate documents from the text of the manuscript. Do not use ditto marks. Center the table number at the top of the page and the title of the table beneath it.

A reasonable number of black-and-white illustrations are permitted without extra charge to the author. Figures must be of suitable quality for publication. Resolution for halftone images should be 300 dots per inch (dpi) at the size it will appear in print. Resolution for line art should be 1200 dpi at the size it will appear in print. All images should be at least 5 inches wide. Preferably, format for digital files should be TIFF (Tagged image file format). Images submitted in software-specific proprietary formats (e.g., PowerPoint, Harvard Graphics, Visio, etc.) must meet specific conditions. Instructions for preparing artwork for online submission can be found at www.ees.elsevier.com/transres.

Consistency in size of illustrations within the article is strongly preferred. Any special instructions regarding sizing should be clearly noted. Arrangements for the use of figures requiring special handling may be made with the Editor at an additional charge.

Legends for figures should be typed double-spaced on a separate page after the References.

Avoid duplicating previously published material. If it is necessary to use a copyrighted table, figure, or data, the figure legend or table footnote should give full credit to the original source and should state that the material is reprinted with permission.

Discussion. The discussion should set the results in context and set forth the major conclusions of the authors. Information from the Introduction or Results section should not be repeated unless necessary for clarity. The authors’ speculations concerning the possible implications of the findings may be presented in this section but should be clearly separated from the direct inferences. As the Journal and its audience are multidisciplinary, we encourage the inclusion of a short concluding paragraph under the subheading “Speculations,” which would point out and clearly denote such broader possibilities for the general readership.

Acknowledgment(s)

In addition to the customary recognition of nonauthors who have been helpful to the work described, this section must disclose, where appropriate, all sources of support for the investigation, any potential conflicts of interest, and clinical trial registry information. Additionally, include statements that all authors have read the journal’s authorship agreement and policy on disclosure of potential conflicts of interest.

References. All references must be cited in the text. These should be numbered serially in the text and listed, in the order cited, after any personal acknowledgments. References should follow the standards summarized by the International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and detailed in the National Library of Medicine’s Citing Medicine. Journal abbreviations should conform to the style of the Cumulated Index Medicus. If not listed in the CIM, journal titles should not be abbreviated. Authors are responsible for the accuracy of their references. Note: Unpublished results and personal communications do not belong in the reference list; they should be cited parenthetically in the text.

EXAMPLES (if six or fewer authors, list all; if seven or more, list first three and add et al.):

Journal articles:


Books:


Chapters in books:


Color Figures

Authors are encouraged to submit color figures, which will be published online at no cost; however, the expense of reproducing color figures in print must be borne by the authors. The charge for reproduction of color figures is $650 for the first figure and $100 for each subsequent figure. Any figure submitted in color and requiring color for adequate
representation of data-as judged by the reviewers-will be reviewed and processed with the understanding that the figure will appear in color in the printed version of the journal at the author’s expense. Authors unable to pay color figure charges may request a waiver in the cover letter at the time of submission.

Permissions and patient consent forms
Direct quotations, tables, or illustrations that have appeared in copyrighted material must be accompanied by written permission for their use from the copyright owner and original author, along with complete information as to source. Photographs of identifiable persons must be accompanied by signed releases showing informed consent.

Disclosure of Potential Conflicts of Interest
All authors are required to disclose potential conflicts of interest relevant to the subject of their manuscript at the time of submission. Conflicts of interest may arise when authors or immediate family members have a financial or personal relationship with organizations that could potentially be perceived as influencing the described research. Financial relationships include compensation for services (e.g., employment, consulting fees, honoraria, expert testimony, advisory boards, speaker’s bureau), equity interest (e.g., stocks, stock options, bonds, or other ownership interests), intellectual property rights (e.g., patents filed or pending, copyrights, royalties), and direct research support (e.g., grants, contracts, or material support). Disclosure of information about potential conflicts of interest is intended to improve transparency and allow readers to form their own judgments of competing influences on the described research.

Andrew Miller, PhD
Executive Publisher, Elsevier
The Boulevard, Langford Lane, Oxford OX5 1GB, UK
Email: andrew.miller@elsevier.com